Article
Erlotinib for Patients with EGFR Wild-Type Metastatic NSCLC: a Retrospective Biomarkers Analysis.
Pathology oncology research : POR - 1 Apr 2019
Inno Alessandro, Di Noia Vincenzo, Martini Maurizio, D'Argento Ettore, Di Salvatore Mariantonietta, Arena Vincenzo, Schinzari Giovanni, Orlandi Armando, Larocca Luigi Maria, Cassano Alessandra, Barone Carlo
Abstract excerpt
Erlotinib is approved for the treatment of patients with EGFR mutation positive, metastatic NSCLC. It is also approved as second/third line therapy for EGFR mutation negative patients, but in this setting the benefit of erlotinib is modest and there is no validated biomarker for selecting EGFR wild-type patients who may benefit the most from the treatment. We retrospectively assessed EGFR and K-RAS mutational...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.